These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 8479739

  • 1. Mutation of a phosphorylation site in the DNA-binding domain is required for redox-independent transactivation of AP1-dependent genes by v-Jun.
    Oehler T, Pintzas A, Stumm S, Darling A, Gillespie D, Angel P.
    Oncogene; 1993 May; 8(5):1141-7. PubMed ID: 8479739
    [Abstract] [Full Text] [Related]

  • 2. Amino acid substitutions modulate the effect of Jun on transformation, transcriptional activation and DNA replication.
    Morgan IM, Asano M, Håvarstein LS, Ishikawa H, Hiiragi T, Ito Y, Vogt PK.
    Oncogene; 1993 May; 8(5):1135-40. PubMed ID: 8479738
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts.
    Basso J, Briggs J, Findlay C, Bos T.
    Oncogene; 2000 Oct 05; 19(42):4876-85. PubMed ID: 11039905
    [Abstract] [Full Text] [Related]

  • 6. Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins.
    Kataoka K, Noda M, Nishizawa M.
    Oncogene; 1996 Jan 04; 12(1):53-62. PubMed ID: 8552399
    [Abstract] [Full Text] [Related]

  • 7. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G, Gilmore TD.
    Oncogene; 1993 Mar 04; 8(3):721-30. PubMed ID: 8437855
    [Abstract] [Full Text] [Related]

  • 8. The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site.
    Bost F, Caron L, Vial E, Montreau N, Marchetti I, Dejong V, Defize L, Castellazzi M, Binétruy B.
    Oncogene; 2001 Nov 01; 20(50):7425-9. PubMed ID: 11704873
    [Abstract] [Full Text] [Related]

  • 9. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors.
    Vial E, Perez S, Castellazzi M.
    Oncogene; 2000 Oct 12; 19(43):5020-9. PubMed ID: 11042689
    [Abstract] [Full Text] [Related]

  • 10. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S, Brown PH, Birrer MJ.
    Oncogene; 1996 Mar 07; 12(5):1043-53. PubMed ID: 8649795
    [Abstract] [Full Text] [Related]

  • 11. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.
    Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M.
    Nature; 1991 Dec 12; 354(6353):494-6. PubMed ID: 1749429
    [Abstract] [Full Text] [Related]

  • 12. Efficient induction of fibrosarcomas by v-jun requires mutations in the DNA binding region and the transactivation domain.
    Morgan IM, Håvarstein LS, Wong WY, Luu P, Vogt PK.
    Oncogene; 1994 Oct 12; 9(10):2793-7. PubMed ID: 8084584
    [Abstract] [Full Text] [Related]

  • 13. The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: implications for SAPK/JNK-mediated signal transduction.
    Kilbey A, Black EJ, Unlu M, Gillespie DA.
    Oncogene; 1996 Jun 06; 12(11):2409-18. PubMed ID: 8649782
    [Abstract] [Full Text] [Related]

  • 14. Mitogenesis of quiescent chick fibroblasts by v-Src: dependence on events at the membrane leading to early changes in AP-1.
    Catling AD, Wyke JA, Frame MC.
    Oncogene; 1993 Jul 06; 8(7):1875-86. PubMed ID: 8510932
    [Abstract] [Full Text] [Related]

  • 15. In vivo viral and cellular Jun complexes exhibit differential interaction with a number of in vitro generated 'AP-1- and CREB-like' target sequences.
    Hadman M, Loo M, Bos TJ.
    Oncogene; 1993 Jul 06; 8(7):1895-903. PubMed ID: 8510933
    [Abstract] [Full Text] [Related]

  • 16. Jun and v-jun contain multiple regions that participate in transcriptional activation in an interdependent manner.
    Angel P, Smeal T, Meek J, Karin M.
    New Biol; 1989 Oct 06; 1(1):35-43. PubMed ID: 2518690
    [Abstract] [Full Text] [Related]

  • 17. Differential and antagonistic effects of v-Jun and c-Jun.
    Gao M, Morgan I, Vogt PK.
    Cancer Res; 1996 Sep 15; 56(18):4229-35. PubMed ID: 8797597
    [Abstract] [Full Text] [Related]

  • 18. TOJ3, a target of the v-Jun transcription factor, encodes a protein with transforming activity related to human microspherule protein 1 (MCRS1).
    Bader AG, Schneider ML, Bister K, Hartl M.
    Oncogene; 2001 Nov 08; 20(51):7524-35. PubMed ID: 11709724
    [Abstract] [Full Text] [Related]

  • 19. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ, Rhim JS, Schlegel R, Vousden KH, Colburn NH.
    Oncogene; 1998 May 28; 16(21):2711-21. PubMed ID: 9652737
    [Abstract] [Full Text] [Related]

  • 20. v-Jun downregulates the SPARC target gene by binding to the proximal promoter indirectly through Sp1/3.
    Chamboredon S, Briggs J, Vial E, Hurault J, Galvagni F, Oliviero S, Bos T, Castellazzi M.
    Oncogene; 2003 Jun 26; 22(26):4047-61. PubMed ID: 12821939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.